Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22716163 | 0.88 | CA1 (0.36) | ALDH1A1GAAMAPTLMNACA1 | |
| SCHEMBL29439729 | 0.88 | CA1 (0.36) | ALDH1A1GAAMAPTLMNACA1 | |
| SCHEMBL16856866 | 0.82 | MEN1 (0.37) | ALDH1A1LMNAMEN1KMT2ATDP1 | |
| SCHEMBL29354307 | 0.81 | ALDH1A1 (0.36) | ALDH1A1GAAMAPTLMNACA1 | |
| SCHEMBL3487390 | 0.81 | ALDH1A1 (0.36) | ALDH1A1GAAMAPTLMNACA1 | |
| SCHEMBL15335154 | 0.74 | HTT (0.36) | ALDH1A1HTTMEN1KMT2ATDP1 | |
| SCHEMBL30550979 | 0.74 | HTT (0.36) | ALDH1A1HTTMEN1KMT2ATDP1 | |
| SCHEMBL16857376 | 0.74 | MBOAT4 (0.32) | — | |
| SCHEMBL14486780 | 0.72 | ERN1 (0.47) | ALDH1A1GAAMAPTCA1CA2 | |
| SCHEMBL14912102 | 0.71 | ERN1 (0.39) | ALDH1A1GAAMAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4186901-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | Cytosinlab Therapeutics Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | FLT3, ERBB2, ABL1 | ALDH1A1 2716/4885GAA 644/4885MAPT 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.